MYOGEN, INC.Stock Purchase Agreement • August 28th, 2003 • Myogen Inc • Colorado
EXHIBIT 10.34 SECURITIES PURCHASE AGREEMENT dated as of September 24, 2004,Securities Purchase Agreement • September 29th, 2004 • Myogen Inc • Pharmaceutical preparations • New York
MYOGEN, INC.License Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Colorado
JOINT FILING AGREEMENTJoint Filing Agreement • October 8th, 2004 • Myogen Inc • Pharmaceutical preparations
Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit (the "Schedule 13D"), and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. This Agreement may be executed in one or more counterparts.
RECITALSLease • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations
MYOGEN, INC.Myogen Inc • August 28th, 2003 • Delaware
CONFIDENTIAL THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE...Myogen Inc • August 28th, 2003 • California
MYOGEN, INC.Preferred Stock Purchase Agreement • August 28th, 2003 • Myogen Inc • Colorado
RECITALSIndemnity Agreement • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations • Delaware
EXHIBIT 10.29 [/\#/\] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS...License Agreement • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations
MYOGEN, INC.Myogen Inc • August 28th, 2003 • Delaware
WITNESSETHLicense Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Illinois
MYOGEN, INC., ISSuER AND [TRUSTEE], TRUSTEE INDENTUREMyogen Inc • November 16th, 2005 • Pharmaceutical preparations • New York
RECITALSInvestor Rights Agreement • August 28th, 2003 • Myogen Inc • Colorado
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • August 28th, 2003 • Myogen Inc • Colorado
EXHIBIT 10.34 [DATE] VIA HAND DELIVERY [Name] Myogen, Inc. 7575 West 103rd Avenue, Suite 102 Westminster, CO 80021 Re: Employment and Retention Agreement Dear [Name]: In consideration of your continued employment as [Position], Myogen, Inc. (the...Myogen Inc • May 9th, 2006 • Pharmaceutical preparations • Colorado
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. PATENT...Patent License Agreement • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations • Texas
WITNESSETHExclusive License Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Illinois
EXHIBIT 10.20 [*#*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Transfer Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Colorado
EXHIBIT 10.10 [DATE] VIA HAND DELIVERY [Name] Myogen, Inc. 7575 West 103rd Avenue, Suite 102 Westminster, CO 80021 Re: Employment and Retention Agreement Dear [Name]: In consideration of your continued employment as [Position], Myogen, Inc. (the...Myogen Inc • March 15th, 2005 • Pharmaceutical preparations • Colorado
MYOGEN, INC., ISSuER AND [TRUSTEE], TRUSTEE INDENTUREMyogen Inc • June 3rd, 2005 • Pharmaceutical preparations • New York
EXHIBIT 10.22 [*#*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Sponsored Research Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Texas
RECITALSPatent and Technology License Agreement • March 1st, 2004 • Myogen Inc • Pharmaceutical preparations
INTRODUCTIONDevelopment and Commercialization Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Massachusetts
MYOGEN, INC.Series D Preferred Stock Purchase Agreement • August 28th, 2003 • Myogen Inc • Colorado
PREAMBLELicense Agreement • May 9th, 2006 • Myogen Inc • Pharmaceutical preparations • New York
EXHIBIT 10.24 [/\#/\] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Collaboration and Option Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Massachusetts
Repayment Period: 36 months Treasury Note Maturity: 36 months Loan Margin: 770 basis pointsVenture Loan and Security Agreement • August 28th, 2003 • Myogen Inc • California
MYOGEN, INC.Myogen Inc • October 1st, 2003 • Pharmaceutical preparations • New York
THIRD AMENDMENT TO THE LICENSE AGREEMENT (ENOXIMONE) BY AND BETWEEN AVENTIS PHARMACEUTICALS INC. (FORMERLY HOECHST MARION ROUSSEL, INC.) AND MYOGEN, INC.License Agreement • March 15th, 2005 • Myogen Inc • Pharmaceutical preparations
ExhibitA-2 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (For HDAC Inhibitor Compounds)Development and Commercialization Agreement • August 9th, 2006 • Myogen Inc • Pharmaceutical preparations • Massachusetts
This License, Development and Commercialization Agreement (this “Agreement”) is made this day of , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.
Myogen, Inc. 4,675,082 Shares of Common Stock, par value $0.001 per share Underwriting AgreementMyogen Inc • September 16th, 2005 • Pharmaceutical preparations
As representatives of the several Underwriters named in Schedule A hereto, c/o Goldman, Sachs & Co., 85 Broad Street, New York, New York 10004
AMENDMENT TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • May 26th, 2005 • Myogen Inc • Pharmaceutical preparations
This Amendment to Collaboration and Option Agreement (“Amendment”) is entered into as of May 23, 2005 (the “Amendment Date”) by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 W. 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.
Exhibit A-1 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • August 9th, 2006 • Myogen Inc • Pharmaceutical preparations • Massachusetts
This License, Development and Commercialization Agreement (this “Agreement”) is made this day of , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.
THIRD AMENDMENT TO LEASELease • October 1st, 2004 • Myogen Inc • Pharmaceutical preparations
This Third Amendment to Lease Agreement (“Third Amendment”) is to be effective upon the closing of the Purchase and Sale Contract, Church Ranch Business Park, entered into by and between Scott Kaufman (“Landlord”) and LaSalle Bank, N.A., made and entered into effective as of July 30, 2004 (“Effective Date”) and is entered into by and between Landlord and Myogen, Inc. (“Tenant”). The Tenant and Landlord may be referred to herein as the “Parties” and either one of them may be referred to herein as a “Party”.
